Prime Medicine Inc., a biotechnology company focusing on innovative genetic therapies, has announced the successful closing of its public offering, raising approximately $144.2 million. The offering consisted of 43,700,000 shares of common stock, including the full exercise of the underwriters' option to purchase an additional 5,700,000 shares, priced at $3.30 per share. Notably, the Cystic Fibrosis Foundation purchased 1,818,181 shares without any discounts or commissions. The offering was managed by TD Cowen and BMO Capital Markets as joint book-running managers. The proceeds are expected to support Prime Medicine's continued development of curative genetic therapies.